Oncotelic Therapeutics, Inc. (OTLC)

Import this data to Google Sheets with:

=jivedata("OTLC","financials")

Full statements spill as a table. For one cell: =jivedata("OTLC","Revenue") or =jivedata("OTLC","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Oncotelic Therapeutics, Inc.

OTLC • CIK 0000908259

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$61.143	—	$4.357	$4.903
General and Administrative Expense	$573.726	$376.013	$3,182.242	$5,961.58
Operating Income (Loss)	$-6,648.015	$-3,576.013	$-3,186.599	$-5,716.483
Goodwill, Impairment Loss	$6,083.146	$3,200	$3,200	$3,200
Operating Expenses	$6,718.015	$3,576.013	$3,186.599	$5,966.483
Net Income (Loss) Attributable to Noncontrolling Interest	$-302.972	$-255.527	$-254.917	$-214.598
Net Income (Loss) Attributable to Parent	$-7,903.093	$-4,523.932	$249,279.832	$247,495.063
Weighted Average Number of Shares Outstanding, Basic	396,165,575	404,396,473	421,045,524	458,781,392
Weighted Average Number of Shares Outstanding, Diluted	396,165,575	—	422,234,747	459,970,615
Gain (Loss) on Investments	$12.706	$12.706	$365,346.775	$365,346.775
Interest Expense, Other	—	$857.723	$885.488	$977.502
Derivative, Gain (Loss) on Derivative, Net	$-225.074	$-280.402	$353.572	$-58.47
Gain (Loss) on Extinguishment of Debt	$-373.142	$-88.258	$-1,058.976	$-1,058.976
Nonoperating Income (Expense)	$-1,558.05	$-1,203.446	$363,761.514	$364,546.948
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	$360,574.915	$360,574.915
Income Tax Expense (Benefit)	—	—	$111,550	$111,550
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-8,206.065	$-4,779.459	$249,024.915	$247,280.465

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Other, Gross	$1,101.76	$1,101.76	$1,101.76	$1,101.76
Goodwill	$5,988.23	$2,788.23	$2,788.23	$2,788.23
Investment Owned, at Fair Value	$22,653.225	$22,653.225	$388,000	$388,000
Assets	$30,014.952	$26,677.426	$393,088.242	$394,750.732
Convertible Debt, Noncurrent	$1,898.468	$1,898.468	—	$1,854.395
Deferred Tax Liabilities, Gross	—	—	$111,550	$111,550
Liabilities	$18,403.415	$19,199.914	$131,356.683	$131,311.353
Cash	—	$86.128	$88.857	$186.014
Restricted Cash	$20	$20	$20	$20
Accounts Receivable, after Allowance for Credit Loss, Current	$18.976	$18.976	$51.324	$2.058
Prepaid Expense and Other Assets, Current	—	—	$1,038.071	$1,252.67
Assets, Current	$271.737	$134.211	$1,198.252	$1,460.742
Accounts Payable and Accrued Liabilities, Current	$2,437.321	$2,437.167	$2,571.123	$2,554.999
Business Combination, Contingent Consideration, Liability, Current	$2,625	$2,625	$2,625	$2,625
Derivative Liability, Current	$423.214	$703.616	$350.044	$337.256
Notes Payable, Current	$8,066.957	—	—	$8,066.957
Liabilities, Current	$16,504.947	$19,199.914	$18,143.278	$17,906.958
Preferred Stock, Value, Issued	—	—	$0.244	$0.509
Common Stock, Value, Issued	$3,991.839	$4,072.899	$4,425.968	$4,570.125
Additional Paid in Capital	$41,655.026	$42,219.4	$47,095.219	$50,556.882
Retained Earnings (Accumulated Deficit)	$-33,516.736	$-38,040.668	$211,239.164	$209,433.535
Stockholders' Equity Attributable to Parent	$12,130.129	$8,251.631	$262,760.595	$264,561.051
Stockholders' Equity Attributable to Noncontrolling Interest	$-518.592	$-774.119	$-1,029.036	$-1,121.672
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$11,611.537	$7,477.512	$261,731.559	$263,439.379
Preferred Stock, Shares Authorized	—	—	15,000,000	15,000,000
Preferred Stock, Shares Issued	—	—	24.388	50,900
Common Stock, Shares Authorized	750,000,000	750,000,000	750,000,000	750,000,000
Common Stock, Shares, Issued	399,184,128	407,289,618	442,596,856	457,012,796

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-8,206.065	$-4,779.459	$249,024.915	$247,280.465
Net Cash Provided by (Used in) Operating Activities	$-1,321.047	$-740.267	$-1,383.145	$-1,524.479
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-71.047	$-84.267	$2.729	$97.992
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$190.405	$106.128	$108.857	$93.298
Goodwill, Impairment Loss	$6,083.146	$3,200	$3,200	$3,200
Proceeds from Convertible Debt	$966.425	—	$478	$478
Amortization of Debt Issuance Costs and Discounts	$301.917	$122.141	$198.053	$418.972
Proceeds from Short-term Debt	$1,410	$656	$907.874	$670.796
Gain (Loss) on Sale of Investments	$12.706	$12.706	$365,346.775	$365,346.775
Net Cash Provided by (Used in) Financing Activities	$1,250	$656	$1,385.874	$1,622.471
Deferred Income Tax Expense (Benefit)	—	—	$111,550	$111,550
Share-based Payment Arrangement, Noncash Expense	$902.141	—	$2,378.836	$2,378.836
Gain (Loss) on Extinguishment of Debt	$-373.142	$-88.258	$-1,058.976	$-1,058.976
Derivative, Gain (Loss) on Derivative, Net	$-225.074	$-280.402	$353.572	$-58.47
Interest Paid, Excluding Capitalized Interest, Operating Activities	$390.561	$365.94	$369.983	$357.93
Income Taxes Paid, Net	$1.6	$1.6	$1.6	$1.6
Increase (Decrease) in Prepaid Expense and Other Assets	$40.392	$-53.249	$-0.657	$212.455
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$-72.771	$293.184	$103.711	$134.689
Increase (Decrease) in Accounts Payable, Related Parties	$26.836	$1.958	$2.054	$2.054

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("OTLC","financials")

Full statements spill as a table. For one cell: =jivedata("OTLC","Revenue") or =jivedata("OTLC","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.